St. Charles, Missouri, resident Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now ...

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

Myra Solano Garcia, who has Alzheimer's, says the drug Kisunla may be one reason she can still drive, cook, and sing.

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.

There are now two fully approved drugs on the market that can, sometimes, slow down the progression of Alzheimer's disease.

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...